Johnson & Johnson's agreement to gradually phase out 'trace amounts of potentially cancer-causing chemicals' from its Baby Shampoo should not be limited, restricted to the U.S. market, Cancer Prevention Coalition says

Michelle Rivera

Michelle Rivera

Dec 16, 2011 – Enhanced Online News

CHICAGO , December 16, 2011 (press release) – The following is an opinion editorial provided by Samuel S. Epstein, M.D., Chairman of Cancer Prevention Coalition:

“the label of a cosmetic product shall bear a warning statement to prevent a health hazard that may be associated with the product.”

The Campaign for Safe Cosmetics must be congratulated for securing a 11/15/11 agreement with Johnson & Johnson “for reducing or gradually phasing out - - trace amounts of potentially cancer-causing chemicals” from Baby Shampoo, “one of its signature products.” However, this agreement is limited and restricted to the U.S. market.

There are two carcinogenic ingredients in Johnson & Johnson’s Baby Shampoo, dioxane and quaternium 15. Dioxane is a well-recognized contaminant in alcohol ethoxylates, a group of four ingredients, laureths, oleths, polyethylene glycol and polysorbates. Quaternium 15 is a precursor of two carcinogens, formaldehyde and nitrosamine. Johnson & Johnson has committed to “reducing or gradual phasing out” dioxane and quaternium-15 in their U.S., but not in their international products.

However limited, Johnson & Johnson’s response is in sharp and disturbing contrast to the silence of the Food and Drug Administration (FDA). This federal agency has still failed to enforce the explicit requirements of the 1938 Federal Food Drug and Cosmetic Act. This directs the FDA to require that “the label of a cosmetic product shall bear a warning statement to prevent a health hazard that may be associated with the product.”

The regulatory failure of the FDA extends to its failure to respond to the Cancer Prevention Coalition’s extensively documented 1996 Citizen Petition “Seeking A Cancer Warning On Cosmetic Products Containing (the carcinogen) Diethanolamine.” FDA’s regulatory failure extends still further to the Coalition’s 2008 Petition, “Seeking A (ovarian) Cancer Warning On Talc Products Used By Premenopausal for Women’s Genital Dusting.” Both Petitions, endorsed by leading cancer prevention experts, requested the FDA to ban or suspend approval of these products which still pose an “Imminent Hazard,” or minimally to require their labeling with a “Caution” or other such warning. However, the FDA has still failed to respond.

Concerns on the cancer risks of talc, dioxane, formaldehyde, nitrosamine, and ethylene oxide, besides other prohibited and restricted carcinogenic ingredients in cosmetics and personal care products, are not new. They were detailed in my 2001 “Unreasonable Risk: How To Avoid Cancer From Cosmetics and Personal Care Products,” and 2009 “Healthy Beauty” books.

As published in the February 25, 2011 Science Insider editorial, "Advancing Regulatory Science," FDA Commissioner, Dr. Hamburg, claimed that FDA's regulations must be based on "better predictive models - - functional genomics, proteomics, and metabolomics," rather than "high dose animal [carcinogenicity] studies - - unchanged for decades."

Dr. Hamburg's dismissal of standard carcinogenicity tests is bizarre. Their scientific validity has been endorsed by other Federal regulatory agencies, the National Toxicology Program, the International Agency for Research on Cancer, besides the April 2010 President's Cancer Panel. Furthermore, as stipulated in the 1938 Federal Food Drug and Cosmetic Act, the FDA is charged with regulating food, drugs, and cosmetics based on standard toxicology and carcinogenicity tests. Moreover, the FDA is not charged with, let alone capable of developing irrelevant "tests that incorporate the mechanistic underpinnings of disease."

As warned by Senator Edward Kennedy at the 1997 Senate Hearings on the FDA Reform Bill, “The cosmetics industry has borrowed a page from the playbook of the tobacco industry by putting profits ahead of public health.” This warning remains current.

Samuel S. Epstein, M.D. is professor emeritus of Environmental and Occupational Medicine at the University of Illinois at Chicago School of Public Health; Chairman of the Cancer Prevention Coalition; and former President of the Rachel Carson Trust. His awards include the 1998 Right Livelihood Award and the 2005 Albert Schweitzer Golden Grand Medal for International Contributions to Cancer Prevention. He is the author of over 270 scientific articles and 20 books on the causes and prevention of cancer, including the Unreasonable Risk Book: How To Avoid Cancer from Cosmetics and Personal Care Products, The Neways Story (2001, Environmental Toxicology), the groundbreaking The Politics of Cancer (1979, Doubleday Books), Healthy Beauty (2010, BenBella Books), and National Cancer Institute And American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest (2011, Xlibris Publishing).

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.


About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025 795

+1 (310) 558 0008
+1 (310) 558 0080 (FAX)

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.